Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC 704865 IND 7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer.

Trial Profile

A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC 704865 IND 7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Feb 2012 Health-related quality-of-life substudy results published in the Journal of Pain and Symptom Management.
    • 02 Mar 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top